Home
    Disclaimer
    ← Back to MiPLA
    MiPLA molecular structure

    MiPLA Stats & Data

    Psychedelic Research-chemical
    Lamide
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)

    Receptor Binding

    5-HT2A partial agonist

    History & Culture

    MiPLA was originally synthesized by Albert Hofmann at Sandoz Laboratories as part of the foundational structure-activity relationship research into LSD. Eli Lilly and Company subsequently filed a patent for the compound in 1956, with formal publication following in 1961. The compound underwent more detailed investigation during the 1990s by David E. Nichols and his research team at Purdue University. MiPLA has primarily served as a pharmacological research tool for elucidating the serotonergic mechanisms through which LSD produces its hallucinogenic effects, with particular focus on its binding characteristics at the 5-HT2A receptor. Alexander Shulgin also documented early human trials with the substance in his "Pharmacology Notes #9" and "Pharmacology Notes C," reporting that subjects experienced LSD-like psychedelic effects at doses suggesting a potency approximately two to three times lower than LSD. MiPLA first emerged on the recreational drug market as a novel designer drug around 2018.

    Effect Profile

    Curated + 7 Reports
    Psychedelic 4.9

    Moderate headspace with mild visuals and body load

    Visual Intensity×3
    5
    Headspace Depth×3
    6
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    4
    Based on reports from:
    Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki MiPLA

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    90% ●○○
    1P-LSD
    90% ●○○
    AL-LAD
    90% ●○○
    ETH-LAD
    90% ●○○
    ALD-52
    90% ●○○

    Experience Report Analysis

    Erowid
    7 Reports
    2018–2020 Date Range
    6 With Age Data
    13 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 7 experience reports (7 Erowid)

    7 Reports
    13 Effects Detected
    7 Positive
    3 Adverse
    3 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 7

    Music Enhancement 85.7% 70%
    Focus Enhancement 71.4% 70%
    Stimulation 71.4% 70%
    Tactile Enhancement 71.4% 70%
    Color Enhancement 57.1% 70%
    Body High 57.1% 70%
    Empathy 42.9% 70%

    Adverse Effects 3

    Anxiety 57.1% 70%
    Memory Suppression 42.9% 70%
    Nausea 42.9% 70%

    Real-World Dose Distribution

    62K Doses

    From 9 individual dose entries

    Sublingual (n=8)

    Median: 0.17mg 25th: 0.1mg 75th: 0.2mg 90th: 0.2mg
    mg/kg median: 0.002 mg/kg 75th: 0.003

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria Unscheduled (grey area) Not specifically prohibited but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) due to structural similarity to LSD.
    Germany NpSG controlled Regulated under the Neue Psychoaktive Substanzen Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to distribute, administration to others, and commercial trading are prohibited offenses. Possession is technically illegal but does not carry penalties.
    Switzerland Controlled (Verzeichnis E) Classified as a controlled substance under Verzeichnis E point 263 as a defined derivative of lysergic acid. Exempted when used for legitimate scientific or industrial purposes.
    United States Unscheduled Not specifically scheduled under the Controlled Substances Act. May be prosecuted under the Federal Analogue Act as a structural analogue of LSD when intended for human consumption.

    References

    Data Sources

    Cited References

    ← Back to MiPLA